MacroGenics | MGNX - Operating Expenses

Stock Price
4.25
Daily Change
0.09 2.16%
Monthly
24.63%
Yearly
168.99%
Q2 Forecast
4.16

MacroGenics reported $21.2M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Genmab DKK 798M 235M Dec/2025
Geron USD 52.07M 6.73M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Xencor USD 82.38M 513K Mar/2026